Each month, subscribers to The Formulary®Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The July 2002 Formulary monograph topics are olmesartan medoximil, fulvestrant, adalimumab, secretin, and duloxetine. The DUE is on olmesartan medoximil.
Get full access to this article
View all access options for this article.
References
1.
Arixtra package literature.Organon Sanofi-Synethlabo LLC; December 2001.
2.
Anonymous.Pentasaccharide (Org 31540/SR90107A) prevents more venous thromboembolic events than enoxaparin in four clinical trials into thrombosis prophylaxis following orthopedic surgery.PRNewswire.www.prnewswire.com. Accessed on September 5, 2000.
3.
LormeauJ.C.Determination of the anti-factor Xa activity of the synthetic pentasaccharide SR 90107A/ORG 31540 and of two structural analogues.Thromb Res.1997; 85: 67–75.
4.
PetitouM.Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).J Med Chem.1997; 40: 1600–7.
5.
HerbertJ.M.Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.Blood.1998; 91: 4197–205.
6.
HerbertJ.M.Biochemical and pharmacological properties of SANORG 32701. Comparison with the ‘synthetic pentasaccharide’ (SR 90107A/ORG 31540) and standard heparin.Circ Res.1996; 79: 590–600.
7.
TurpieA.G.A synthetic pentasaccharide for the prevention of deepvein thrombosis after total hip replacement.N Engl J Med.2001; 344: 619–25.
8.
HeraultJ.P.Comparative effects of two factor Xa inhibitors: The synthetic pentasaccharide SR 90107A/ORG 31540 and DX 9065 on free and clot-bound prothrombinase.Thromb Haemost.1997; 76(suppl): P1200.
9.
LormeauJ.C., HeraultJ.P.The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa.Thromb Haemost.1995; 74: 1474–7.
10.
LormeauJ.C.Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin.Thromb Haemost.1996; 76: 5–8.
11.
WalengaJ.M.Functionality of pentasaccharide depends on endogenous antithrombin levels [abstract]. 42nd American Society for Hematology Annual Meeting. San Francisco; December 1–5, 2000: 3530. www.hematology.org. Accessed June 13, 2001.
12.
van AmsterdamR.G.M.Evaluation of ORG 31540/SR 90107A in preclinical models of thrombosis.Thromb Haemost.1997; 76(suppl): P2834.
13.
BernatA.The antithrombotic efficacy of the GP IIb/IIIa antagonist SR 121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit.J Cardiovasc Pharmacol.1999; 33: 573–9.
14.
PislaruS.V.Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis.Thromb Haemost.1998; 79: 1130–5.
15.
AmiralJ.Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia.Blood Coagul Fibrinolysis.1997; 8: 114–7.
16.
DonatF.Safety and pharmacokinetics (PK) of co-administration of the first synthetic factor Xa inhibitor and aspirin in human volunteers [abstract]. 42nd American Society for Hematology Annual Meeting. San Francisco; December 1–5, 2000: 226. www.hematology.org. Accessed June 13, 2001.
17.
PaolucciF.Pentasaccharide, the novel specific antithrombotic agent: In vitro protein binding to human plasma and purified antithrombin [abstract].Pharmacotherapy.2001; 21: 1271.
18.
Rembrandt Investigators.Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity. A phase II evaluation.Circulation.2000; 102: 2726–31.
19.
BoneuB.Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man.Thromb Haemost.1995; 74: 1468–73.
20.
FaaijR.A.The influence of renal function on the pharmacokinetics (PK) and pharmacodynamics of ORG31540/SR90107A.Thromb Haemost.1997; 76(suppl): PS379.
ErikssonB., GoteborgO.S.The Penthifra study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) the prevention of venous thromboembolism (VTE) after hip fracture surgery [abstract]. 42nd American Society for Hematology Annual Meeting. San Francisco; December 1–5, 2000: 2110. www.hematology.org. Accessed June 13, 2001.
23.
ErikssonB.I.Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.N Engl J Med.2001; 345: 1298–304.
24.
BauerK.The Pentamaks study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin the prevention of venous thromboembolism (VTE) after elective major knee surgery [abstract]. 42nd American Society for Hematology Annual Meeting. San Francisco; December 1–5, 2000: 2111. www.hematology.org. Accessed June 13, 2001.
25.
BauerK.A.Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.N Engl J Med.2001; 345: 1305–10.
26.
TurpieG.The Pentathlon 2000 study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery [abstract]. 42nd American Society for Hematology Annual Meeting. San Francisco; December 1–5, 2000: 2112. www.hematology.org. Accessed June 13, 2001.
27.
LassenM.R.The Ephesus study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) the prevention of venous thromboembolism (VTE) after elective hip replacement surgery [abstract]. 42nd American Society for Hematology Annual Meeting. San Francisco; December 1–5, 2000: 2109. www.hematology.org. Accessed June 13, 2001.
28.
VuillemenotA.Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent: A pilot study in the setting of coronary angioplasty.Thromb Haemost.1999; 81: 214–20.
29.
CoussementP.K.A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction.Eur Heart J.2001; 22: 1716–24.
30.
Van de WerfF.New data in treatment of acute coronary syndromes.Am Heart J.2001; 142: S16–21.
31.
FaaijR.A.Lack of pharmacokinetic (PK) and pharmacodynamics (PD) interaction between the first synthetic factor Xa inhibitor and warfarin in human volunteers [abstract]. 42nd American Society for Hematology Annual Meeting. San Francisco; December 1–5, 2000: 234. www.hematology.org. Accessed June 3, 2001.
32.
FaaijR.A.Interaction study between ORG 31540/SR90107A (sc) and oral warfarin in healthy volunteers.Thromb Haemost.1997; 76(suppl): P2007.
